Drugs / BCH-BB694
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03282656 | Feb 2018 → May 2026 overdue | sickle cell disease | David Williams | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCH-BB694 | “The investigational therapy involved infusion of autologous CD34+ cells transduced with the BCH-BB694 lentiviral vector, which encodes a short hairpin RNA (shRNA) targeting...” PMID 33283990 ↗ Dec 2020 |
| Action | Inhibit | “BCL11A inhibition” PMID 33283990 ↗ Dec 2020 |
| Route | Intravenous | “Cells will be infused intravenously over 30-45 minutes” NCT03282656 ↗ |
| Target | BCL11A | “targeting BCL11A mRNA” PMID 33283990 ↗ Dec 2020 |